Close Menu
Patsnap eureka →
Patsnap eureka →

KRAS Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy

14 Mins Read
Target Attractiveness Report · Oncology

This KRAS target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP.

PatSnap Life Sciences MCP Servers marketplace

Small GTPase · UniProt P01116 · HGNC:6407 · Pan-cancer driver

Executive Summary — Target Thesis

Target Snapshot
Total Assets
759
Approved Drugs
6
Clinical Assets
106+
Total Deals
56+
✅ Key Strengths
  • Fully validated target. Driver mutation in ~30% of all solid tumors; highest-confidence causal oncogene.
  • Commercial proof. 6 approved drugs since 2021; G12C market validated across NSCLC and CRC.
  • G12D frontier wide open. Zero approved drugs for G12D despite ~40% PDAC prevalence — highest unmet need in KRAS.
  • Richest deal ecosystem. BMS/Mirati ~$4.8B M&A, AZ/Jacobio $2B+, RevMed $2B Royalty Pharma; sustained capital appetite.
  • Modality breadth. Small molecule, PROTAC, TCR-T, vaccines, molecular glues — broadest modality diversification of any oncology target.
⚠️ Key Risks
  • Pathway feedback reactivation. RAS–MAPK reactivation limits single-agent G12C inhibitor durability.
  • G12C market saturated. 6 approved drugs + multiple Phase 3 assets competing for same biomarker-selected population.
  • G12D/pan-KRAS druggability. Non-covalent molecular glues less characterized at scale for oral bioavailability and toxicity.
  • Co-mutation complexity. STK11, KEAP1 co-mutations stratify patients and undermine ICI combinations.

Section I: Target Biology and Druggability

KRAS
GTPase KRas · K-Ras4B · Ki-Ras · KRAS2
UniProt
P01116
HGNC
6407
Protein Class
Small GTPase
Localization
Membrane-associated, intracellular
Associated Diseases
106 direct · 142 roll-up
Cancer Prevalence
~30% all solid tumors
Patent Families
6,217+
Target Benchmark Snapshot
Validation Driver mutation in ~30% of all cancers; MAPK/RAF/PI3K pathway nexus; causal driver, not bystander
Druggability G12C: mutant-Cys12 switch-II pocket (SIIP), covalent GDP-OFF lock. G12D/G12V: requires RAS-ON molecular glues, PROTACs, or macrocycles
Approvals 6 approved drugs (2021–2026), all G12C small-molecule covalent inhibitors
Modalities Small molecule 357 · PROTAC 135 · TCR-T 55 · Molecular glues · siRNA · Vaccines · ADCs
BD Velocity 56+ deals; BMS/Mirati ~$4.8B M&A; AZ/Jacobio $2B+; RevMed $2B royalty financing
Mutation Prevalence by Cancer Type
Mutation NSCLC CRC PDAC Endometrial Strategic Priority
G12C ~13% ~3–4% ~1–2% ~3% Approved; crowded; 1L combo next
G12D ~4% ~12% ~40% ~15% Highest unmet need; first approval imminent
G12V ~7% ~10% ~10% ~10% No approved drug; PROTAC/TCR-T pursuing
G12R ~1% ~2% ~20% — PDAC-enriched; early clinical programs
G13D ~2% ~10% ~2% — CRC-enriched; limited dedicated programs
KRAS Signaling Cascade
RTK / Growth Factor
→
RAS-GDP → RAS-GTP (GEF/SOS1)
→
RAF / BRAF activation
→
MEK1/2
→
ERK1/2 (MAPK3/MAPK1) · Cell Proliferation
Oncogenic Mutation (G12C/D/V…)
→
GTPase impaired → Constitutive GTP-ON
→
PI3K / AKT branch
→
Uncontrolled Proliferation / Survival
Oncogenic KRAS mutations lock GTP-ON state by impairing intrinsic GTPase activity and GAP-mediated hydrolysis, driving constitutive MAPK/RAF/PI3K activation.
Multi-layer Mechanism of Action — KRAS Inhibition Strategies
1
Covalent G12C GDP-OFF Lock
Irreversible warhead binds mutant Cys12 in switch-II pocket; traps KRAS in inactive GDP-bound state; blocks GEF-mediated reactivation.
Sotorasib · Adagrasib
2
Non-covalent RAS-ON Molecular Glue
Traps KRAS·GTP:PPIA (cyclophilin A) ternary complex in GTP-ON state; prevents effector engagement; applicable to G12D, G12V, and pan-KRAS mutants.
Zoldonrasib · Daraxonrasib
3
PROTAC-mediated Targeted Degradation
Bifunctional molecule recruits E3 ubiquitin ligase (CRBN/VHL) to KRAS; ubiquitination drives proteasomal degradation; eliminates protein rather than inhibiting it.
Setidegrasib
4
LZTR1-mediated Upstream Ubiquitination
LZTR1 mediates KRAS ubiquitination via BCR (BTB-CUL3–RBX1) E3 complex; provides potential endogenous regulatory handle for upstream intervention strategies.
Exploratory
5
Neoantigen-specific Immune Engagement
HLA-restricted TCR-T cells or KRAS mutation-specific vaccines prime immunological memory targeting G12V/G12D neoepitopes; applicable to mutation types without covalent handle.
ELI-002 · ANOC-003

Section II: Pipeline and Modality Landscape

Development Stage Distribution (~759 total assets)
Preclinical
414
Phase 1/2
88
Phase 3
~10
Approved
6
Discontinued
~60
Modality Breakdown
Small Molecule · 357 PROTAC · 135 TCR-T Cell Therapy · 55 Molecular Glue siRNA Vaccines ADCs
Key Clinical Assets — Modality Differentiation Matrix
Drug Company Modality Target Phase Indication Key Differentiator
Sotorasib Amgen SM covalent (GDP-OFF) KRAS G12C Approved 2021 NSCLC, CRC First-in-class; 800mg QD; CodeBreaK 200
Adagrasib BMS/Mirati SM covalent (GDP-OFF) KRAS G12C Approved 2022 NSCLC, CRC, multi CNS penetration; 600mg BID; KRYSTAL series
Fulzerasib Genfleet/Innovent SM covalent (GDP-OFF) KRAS G12C Approved Aug 2024 NSCLC, CRC First China-originated G12C approval
Garsorasib InventisBio SM covalent (GDP-OFF) KRAS G12C Approved Nov 2024 NSCLC CTA Tianqing collaboration
Glecirasib Jacobio/AZ SM covalent (GDP-OFF) KRAS G12C Approved May 2025 NSCLC, PDAC Pancreatic cancer label; AZ global deal $2B+
Sosimerasib Shanghai Jiyu/Huyabio SM covalent (GDP-OFF) KRAS G12C Approved Feb 2026 NSCLC International expansion via Huyabio
Olomorasib Eli Lilly SM covalent (GDP-OFF) KRAS G12C Phase 3 SUNRAY-01 NSCLC (1L), CRC 1L combo with pembrolizumab; next-gen potency
Divarasib Roche/Genentech SM covalent (GDP-OFF) KRAS G12C Phase 3 NSCLC, CRC Roche combination platform; atezolizumab combos
Zoldonrasib (RMC-9805) Revolution Medicines Molecular glue (RAS-ON) KRAS G12D Phase 3 PDAC, NSCLC First G12D RAS-ON inhibitor in Phase 3; PDAC first
Daraxonrasib (RMC-6236) Revolution Medicines Molecular glue (RAS-ON) pan-RAS Phase 3 PDAC, NSCLC, CRC Broadest RAS coverage; pan-mutant potential
Setidegrasib Arvinas PROTAC KRAS G12D Phase 3 Solid tumors First G12D PROTAC in Phase 3; protein degradation
INCB-161734 Incyte Small molecule KRAS G12D Phase 3 Multiple tumors Incyte oncology expansion into KRAS G12D
ELI-002 Elicio Therapeutics Vaccine (AMP-peptide) KRAS mutations Phase 1/2 NSCLC, CRC, PDAC Immunological memory; adjuvant/preventive strategy
ANOC-003 NeoTrail/HOOKIPA TCR-T cell therapy KRAS mutations Phase 1/2 Solid tumors Neoantigen-specific TCR; cell therapy approach
Clinical Efficacy Benchmark — Approved Assets
Sotorasib · CodeBreaK 200 (Ph3)
Population2L+ G12C NSCLC (n=345)
ORR28%
mPFS5.6m
vs Docetaxel mPFS4.5m
HR (PFS)0.66
Adagrasib · KRYSTAL-1 (Ph1/2)
Population2L+ G12C NSCLC (n=116)
ORR43%
mPFS6.5m
mOS12.6m
Olomorasib · SUNRAY-01 Ph1 (Combination)
Population1L NSCLC + pembrolizumab
ORR (early cohorts)50–70%+
Phase 3 statusSUNRAY-01 ongoing
Adagrasib + cetuximab (KRYSTAL-10 Ph3, 2L KRAS G12C CRC): ORR ~34% vs 2% cetuximab monotherapy — statistically significant head-to-head improvement.
Key Biological Risks — Resistance & Safety Considerations
↺
Pathway feedback reactivation: RTK-mediated RAS–MAPK re-activation upon inhibition limits single-agent durability of G12C inhibitors.
⇄
RAS isoform switching: NRAS/HRAS compensation may emerge as an adaptive resistance mechanism under selective KRAS pressure.
⚠
On-target toxicity (pan-RAS): Physiologic WT KRAS role in normal tissues raises concern for pan-RAS inhibitor therapeutic window.
🧬
Co-mutation complexity: STK11, KEAP1, TP53, NF1 co-mutations stratify patient outcomes and undermine ICI combination efficacy.

Section III: Clinical Evidence Benchmark

Key Trial Results — 216+ clinical trial results for G12C · 648 translational records
Asset / Regimen Trial Population Key Result Confidence
Sotorasib CodeBreaK 200 (Ph3) 2L+ G12C NSCLC · n=345 PFS 5.6m vs 4.5m (docetaxel); HR 0.66; ORR 28% vs 13% High
Adagrasib KRYSTAL-1 (Ph1/2) 2L+ G12C NSCLC · n=116 ORR 43%; mPFS 6.5m; mOS 12.6m High
Adagrasib + cetuximab KRYSTAL-10 (Ph3) 2L G12C CRC ORR ~34% vs 2% cetuximab alone — statistically significant High
Garsorasib + ifebemtinib Ph1b/2 G12C CRC Combination improves ORR over G12C monotherapy Medium
Olomorasib + pembrolizumab SUNRAY-01 (Ph3 ongoing) 1L G12C NSCLC, PD-L1 0–49% Ph1 cohorts: ORR 50–70%+; Ph3 primary endpoint pending Medium · Ph3 pending
Zoldonrasib Phase 3 G12D PDAC, NSCLC Registration-enabling Phase 3 ongoing — first RAS-ON G12D inhibitor Pending
Daraxonrasib Phase 3 pan-KRAS PDAC, NSCLC, CRC Pan-RAS breadth across all KRAS mutations; Phase 3 ongoing Pending
Evidence Watch — Key Upcoming Readouts
→SUNRAY-01 Ph3 primary endpoint — Olomorasib + pembrolizumab 1L NSCLC; potential practice-changing 1L approval
→Zoldonrasib Ph3 PDAC readout — Could be first approved KRAS G12D drug in oncology’s most underserved cancer
→Daraxonrasib Ph3 PDAC results — First proof for pan-RAS efficacy at registration scale
→Setidegrasib Ph3 — First G12D PROTAC proof-of-concept in registration-enabling study

Section IV: Competitive Ranking

Competitive Ranking — Phase 3 & Approved Leaders
Rank Asset Tier Strength Key Risk Next Catalyst
#1 Daraxonrasib (RevMed)
pan-RAS · Molecular glue
 Tier 2 · Phase 3 Pan-RAS breadth covers all KRAS + NRAS/HRAS; $2B Royalty Pharma deal; durable IP moat WT RAS toxicity; oral bioavailability at scale Ph3 PDAC primary endpoint (~2026/27)
#2 Zoldonrasib (RevMed)
KRAS G12D · Molecular glue
 Tier 2 · Phase 3 First RAS-ON G12D inhibitor in Phase 3; PDAC massive unmet need; no approved competitor PDAC stroma/immunosuppression; single-agent activity limitations Ph3 PDAC readout; NDA filing
#3 Olomorasib (Lilly)
KRAS G12C · SM covalent
 Tier 2 · Phase 3 1L combination-first design; early ORR 50–70%+; Lilly clinical platform Must beat chemo+pembro standard; OS data maturation needed SUNRAY-01 Ph3 primary PFS readout
#4 Adagrasib (BMS/Mirati)
KRAS G12C · SM covalent
 Tier 1 · Approved CNS penetrant; broadest approved indication set; KRYSTAL-10 combo positive Competition intensifying in 1L; comparable outcomes vs sotorasib in RW KRYSTAL-12 1L combination readout
#5 Sotorasib (Amgen)
KRAS G12C · SM covalent
 Tier 1 · Approved First-in-class; CodeBreaK 200 Ph3 positive vs docetaxel Market share pressure from next-gen G12C; lower CNS penetration CodeBreaK 202 combination data
#6 Glecirasib (Jacobio/AZ)
KRAS G12C · SM covalent
 Tier 2 · Approved + Global deal First G12C inhibitor approved for PDAC (China); AZ global exclusive validates broader pipeline China-first; global regulatory pathway pending; RevMed PDAC competition Global regulatory filing for NSCLC/PDAC
Clinical Trial Volume by Mutation
G12C
275 trials
Saturated
G12D
87 trials
Frontier
G12D is present in ~40% of PDAC — highest-mortality RAS-mutated cancer — yet has only 87 registered trials vs 275 for G12C. This gap represents the primary commercial white space.

Section V: Deal and Capital Flow

Total Deals
56+
Largest M&A
~$4.8B
BMS/Mirati
RevMed Royalty
$2B
Royalty Pharma
AZ/Jacobio License
$2B+
pan-KRAS global
Deal Chronology — Selected Significant Transactions
  1. Option to Buy — AbbVie ← Kestrel
    KRAS small molecule (Phase 1)
    Up to $1.45B · Big Pharma continues hunting KRAS assets; even Phase 1 commands 10-figure option deals
  2. Global Exclusive License — AstraZeneca ← Jacobio
    JAB-23E73 (pan-KRAS, Phase 1/2)
    $100M upfront + $1.915B milestones · AZ building comprehensive KRAS portfolio; pan-KRAS is the strategic horizon
  3. Royalty Financing — Royalty Pharma → RevMed
    RAS(ON) portfolio (Phase 3)
    $2B · Capital conviction in RevMed pan-RAS platform; Phase 3-stage royalty deal signals approval confidence
  4. Global Exclusive License — Bayer ← Kumquat Biosciences
    Precision oncology (KRAS-related)
    Up to $1.3B · Bayer entering KRAS space via external innovation
  5. M&A Acquisition — BMS ← Mirati
    Adagrasib + MRTX-1133 + pan-KRAS portfolio
    ~$4.8B · Largest KRAS acquisition; BMS consolidated G12C/G12D/pan-KRAS portfolio in one transaction
  6. Global Exclusive License — AstraZeneca ← Yousen Jianheng
    KRAS G12D inhibitor (preclinical)
    $24M upfront + $395M milestones · Preclinical-stage G12D commands $400M+ potential — signals G12D strategic value

Section VI: Intellectual Property Landscape

Total Patent Families
6,217+
Densest IP estate in targeted oncology
Core G12C CoM Expiry
2034–2040
Sotorasib/adagrasib composition-of-matter
IP Themes
5
G12C core · G12C combo · G12D · PROTAC · Biomarker
Patent Milestone Timeline — Key Filing & Strategy Events
  1. F
    G12C Covalent Scaffold — First Filings (Amgen/Array BioPharma/Mirati)
    SIIP-binding covalent warheads; core composition-of-matter patents filed
  2. A
    FDA Approval Patents — Sotorasib & Adagrasib
    Orange Book listings; method-of-use patents for NSCLC/CRC approved indications
  3. P
    G12D & Pan-KRAS Scaffold PCT Filings (Mirati/BMS ≥6 PCT families)
    Quinazoline, azaquinazoline, tetrahydropyridopyrimidine pan-KRAS scaffold strategies
  4. T
    PROTAC & Molecular Glue IP Filings (PAQ, RevMed, Arvinas)
    Three-component composition patents (binder-linker-E3); new defensible IP moat emerging
  5. B
    Biomarker / Companion Diagnostic Patents (Foundation Medicine/Genentech)
    KRAS+STK11+KEAP1 co-mutation signature for ICI response prediction; pending
6,217+ Families
Densest patent
estate in precision
oncology
IP Thematic Clusters — Status & FTO Signal
G12C Covalent Core Active
Amgen · Mirati/BMS · Novartis · Array BioPharma
Core CoM expiring 2034–2040; combination patents extend exclusivity. Dense — high FTO risk for new G12C monotherapy.
G12C Combination Therapy Active + Pending
Amgen · Novartis · Genentech · Mirati/BMS
SHP2+G12C co-patent well-crowded. Densest patent activity area; limited FTO for common combinations.
G12D Inhibitor Scaffolds PCT Pending · Aggressive
Mirati/BMS · RevMed · Yousen Jianheng
Aggressive PCT filing phase; some Mirati families at national-phase expiration risk post-BMS. Open space for distinct G12D chemotypes.
KRAS PROTAC IP Active + Pending
PAQ Therapeutics · RevMed · Arvinas
Three-component composition (binder-linker-E3) more defensible. FTO available with distinct E3 ligase partners beyond CRBN/VHL.
Biomarker / CDx Patents Pending
Foundation Medicine/Genentech · NCI
KRAS+STK11+KEAP1 co-mutation for ICI response prediction. Strategically undervalued; companion diagnostic opportunity.
Novel Mechanisms Early Active
Emory · ISB · Wannan Medical
scFv/CAR-T for G12V; KRAS G12V–JAK1 interaction inhibitors; cyclic peptide G12D. Open white space for early-stage innovation filings.

Section VII: White Space, Risk, and Strategic Matrix

🐂 Bull Case — White Space Opportunities
  • ~2026/27 · First G12D PDAC approval (Zoldonrasib Ph3) — zero approved drugs for highest-mortality KRAS mutation
  • 2025–2026 · SUNRAY-01 Ph3 readout — 1L NSCLC combination could dominate larger patient population than 2L
  • Ongoing · Pan-KRAS/RAS-ON platform (Daraxonrasib) covers all KRAS + NRAS/HRAS — first truly universal RAS inhibitor
  • Emerging · CNS-penetrant G12D/pan-KRAS inhibitor could secure distinct label with limited competition
  • Emerging · PROTAC G12D/G12V with novel E3 ligase creates new IP moat, addresses mutation types without covalent handle
🐻 Bear Case — Key Risks
  • Biological · Feedback reactivation (RTK → KRAS re-activation) limits single-agent durability; combination strategies needed
  • Commercial · G12C market saturated with 6 approved drugs; new entrant differentiation requires compelling 1L story
  • Regulatory/Clinical · PDAC stromal barrier and immunosuppressive microenvironment may limit single-agent RAS-ON activity
  • Technical · Pan-RAS on-target toxicity (WT KRAS inhibition) — therapeutic window characterization at scale incomplete
  • Competitive · Failed SOS1 combination (BI-1701963) signals that not all combination hypotheses translate
Risk Matrix — Severity × Probability
HIGH
R3
R1
MED
R2
R4
LOW
LOW
MED
HIGH
← Probability →
Clinical/Regulatory/IP Risk
Commercial/Market Risk
R1
Pathway Feedback Reactivation
RTK-mediated KRAS re-activation upon G12C inhibitor treatment limits single-agent durability. High probability, high severity for monotherapy programs.
Mitigation: Combination with SHP2/SOS1/MEK inhibitors; RAS-ON molecular glue strategies that prevent reactivation.
R2
G12D/Pan-KRAS Druggability at Scale
Non-covalent molecular glues less characterized at scale for oral bioavailability and WT KRAS on-target toxicity. Medium probability, medium-high severity.
Mitigation: Larger Phase 2 safety cohorts; narrow therapeutic window monitoring; PROTAC parallel development as backup modality.
R3
G12C Market Saturation
6 approved G12C drugs competing for same biomarker-selected population. Commercial differentiation in G12C monotherapy increasingly difficult. High probability for new entrants.
Mitigation: Combination-first 1L design; CNS penetration differentiation; resistance-focused sequencing strategies.
R4
Co-mutation Complexity (STK11/KEAP1)
KRAS+STK11 and KRAS+KEAP1 co-mutations stratify patient outcomes and undermine ICI combination efficacy. Medium probability; high severity for immunotherapy-combination strategies.
Mitigation: Prospective co-mutation biomarker panel in trial design; biomarker-stratified enrollment; companion diagnostic development.
Strategic White Space Map
Priority 1 KRAS G12D Approval in PDAC
Zero approved drugs for PDAC’s most common driver mutation. Zoldonrasib Ph3 ongoing. PDAC 5-year survival ~13%. First-mover commands premium pricing and strong IP moat.
Change trigger: Zoldonrasib/INCB-161734 Ph3 failure or PDAC stromal barrier data limiting efficacy.
Priority 2 1L Combination NSCLC
Olomorasib early 1L data (ORR 50–70%+); larger patient population vs 2L; SUNRAY-01 is the critical catalyst. Wins in 1L would be commercially dominant.
Change trigger: SUNRAY-01 negative PFS primary endpoint; safety interaction issues with pembrolizumab.
Priority 3 KRAS G12V Programs
No approved drug. G12V present in ~7–10% NSCLC, PDAC, CRC. Lacks cysteine for covalent. TCR-T (NCI autologous anti-G12V) limited by HLA-A*02:01 restriction (~45% patients).
Change trigger: PROTAC oral delivery resolution; broader HLA-unrestricted cell therapy platform.
Priority 4 Resistance Management Post-G12C
Multiple resistance mechanisms identified: secondary KRAS mutations, amplification, G12D emergence, MAPK bypass. Re-treatment protocols in infancy. Pan-KRAS/RAS-ON agents positioned for post-G12C resistance.
Change trigger: Durable G12C + SHP2/MEK combinations preempt need for sequential re-treatment agents.

Bottom Line — R&D and BD Implications

BD Implication
·G12C market is M&A-harvested; asset acquisition prices for next-gen G12C are high
·Strategic focus shifting to G12D (PDAC/CRC premium), pan-KRAS, and resistance combination franchises
·AbbVie/Kestrel $1.45B option (Apr 2026) and RevMed $2B Royalty Pharma deal confirm sustained frontier appetite
R&D Decision
·Entry into G12C monotherapy is commercially unwise for new entrants — requires combination-first design or G12D/G12V specificity
·PROTAC/molecular glue justified bets for oncogenotypes without a covalent handle
·Distinct E3 ligase profiles (beyond CRBN/VHL) sidestep Mirati/RevMed IP
R&D Team Priorities
·Co-mutation biomarker panel (STK11, KEAP1, TP53, NF1, KRAS amplification) for patient stratification
·Ex vivo resistance profiling after G12C inhibitor exposure
·Combination dosing schedule optimization: SHP2, SOS1, MEK, immune checkpoint agents
·CNS-penetrant scaffold development for G12C/G12D brain mets indication
KRAS is the most commercially validated, most scientifically diverse, and most deal-active oncology target of this generation. The highest unmet need and greatest commercial upside now resides in KRAS G12D (particularly PDAC) and pan-KRAS strategies.
Epicenter Company
Revolution Medicines
2× Phase 3 assets · $2B Royalty Pharma
Explore PatSnap Life Sciences MCP Servers

Start building target evaluation agents with PatSnap Life Sciences MCP Servers

Share.

Related Posts

Comments are closed.